|
The Board of EESCN comprises a Chairman and four Directors. Together they are responsible for the corporate governance of EESCN. Each brings a unique set of skills and experience to the Network. Dr Hermann Hauser - Chairman Hermann co-founded Amadeus Capital Partners in 1997 with Anne Glover and Peter Wynn. In his long and successful history as an entrepreneur and venture capitalist, he has founded or co-founded companies in a wide range of technology sectors. These include Acorn Computers, Active Book Company, Virata, Net Products, NetChannel, and Cambridge Network Limited. He was a founder director of IQ (Bio), IXI Limited, Vocalis, SynGenix, Advanced Displays Limited, Electronic Share Information Limited and E*Trade UK. At Amadeus Hermann has been a non-executive director of many investee companies including CSR, which provides single chip wireless solutions supporting communications over short-range radio links, and Entropic Research Laboratory, a company that developed voice recognition software, which is now the voice recogniser in Microsoft Word. Entropic was sold to Microsoft in 1999. He is a non-executive director of Plastic Logic, which has developed a process for producing flexible plastic transistors for use in computer displays, and Solexa, which is developing ultra-high throughput DNA sequencing technology. Hermann holds an MA in Physics from Vienna University and a PhD in Physics from the Cavendish Laboratory at King's College, Cambridge. He is a Fellow of the Institute of Physics and of the Royal Academy of Engineering and an Honorary Fellow of King's College, Cambridge. Hermann holds honorary doctorates from the Universities of Bath, Loughborough and from Anglia Polytechnic, and was awarded an Honorary CBE for ‘innovative service to the UK enterprise sector’ in 2001. In 2004, he was made a member of the Government’s Council for Science & Technology. Austrian by birth, Hermann speaks German, English, Italian and French. Julian Hitchcock - Director & Manager Julian is a leading stem cell lawyer, with a particular expertise in relation to the patent and regulatory aspects of cells and tissues. His interest in regenerative medicine goes back to the first clinical trials in the UK of foetal cells in the treatment of Parkinson's Disease, about which he directed the award-winning BBC film, "I Want to be Normal Again" after an education in medicine (favourite subject: embryology). He qualified as a solicitor in 1998: in the IP department of Wragge & Co. After being awarded the Bristol University Diploma in Intellectual Property Law & Practice in 2000, Julian practiced in Melbourne at Blake Dawson Waldron, where he conducted pharmaceutical and biotech patent litigation for substantial clients. In 2004, he joined the Cambridge office of Mills & Reeve, as the firm's specialist life science lawyer. In June 2009, he joined the life science team of the European law firm, Field Fisher Waterhouse LLP, to launch the UK's first dedicated regenerative medicine legal practice. Julian Hitchcock is very active in the advance of the regenerative medicine sector, supporting researchers, businesses and health providers. He divides his time between Cambridge and London. Dr Megan Davies - Director & Company Secretary Megan obtained her PhD from the University of Cambridge for work on pathogenic yeast. After postdoctoral work at NYU Medical School in Manhattan, she joined the Medical Research Council in 1983, as a programme manager in its Head Office in London. In 1996 she moved to Cambridge to become Head of the MRC Centre and Assistant Director of the MRC Laboratory of Molecular Biology. In this role she leads the administrative activities and provides strategic support to the Directors of MRC Units in the region. MRC is a major partner in the 2020 Vision developments on the Cambridge Biomedical Campus, and Megan is a Governor, representing the research partners, of the Cambridge University NHS Foundation Hospital Trust (Addenbrooke’s). Richard Archer - Director Richard Archer is an engineer who has been involved in Cambridge technology companies for 30 years. Originally head of Mechanical Engineering at PA Technology, he was then one of the founders of The Technology Partnership, creating and leading the automation activities before spinning those out to become The Automation Partnership, where he was CEO until retiring in 2004. At TAP, he was the originator of cell culture automation technologies, initially for hormone and vaccine production, and latterly for producing cells to be used in both drug research and regenerative medicine applications. Richard now has a variety of positions and interests including Chair of remedi, a national research programme, led by Loughborough University, exploring process and related issues in taking stem cell and other RM products through to application, Chairman of Axordia, the exploitation company for ES cell research at The Centre For Stem Cell Biology at The University of Sheffield, Chair of Magnecell, a Keele spin-out exploiting magnetic nanoparticles to retain stem cells and direct their differentiation by mechanical stimuli. He also consults for other UK companies on manufacturing issues for cellular therapies, is a Senior Industrial Fellow at The Institute for Manufacturing in Cambridge and advises EPSRC on strategy for innovative manufacturing research. Dr Cathy Prescott - Director Cathy is the founder and Director of Biolatris - a Cambridge-based consultancy specialising in the field of stem cells and regenerative medicine. Cathy also advises universities on innovative models for technology transfer. (Photo by www.garyhopephotography.co.uk)
|
